Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel I Levy

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Kidney International Reports|October 8, 2021
A Retrospective Study of Clinical and Economic Burden of Focal Segmental Glomerulosclerosis (FSGS) in the United StatesKamyar Kalantar-Zadeh, Christine L Baker, J Brian Copley, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 13, 2023
Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapyMartin Schulz, Daniel I Levy, Christos J Petropoulos, et al.
Clinical Transplantation|January 31, 2014
Long-term evaluation of analytical methods used in sirolimus therapeutic drug monitoringDavid W Holt, Didier A Mandelbrot, Michael A Tortorici, et al.
Kidney International Reports|June 25, 2021
PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental GlomerulosclerosisLaurence H Beck, Stephen P Berasi, J Brian Copley, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 30, 2025
Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trialSarah P Sherlock, Daniel I Levy, Avery McIntosh, et al.
The Lancet. Neurology|February 21, 2026
Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled studyFrancesco Muntoni, Andres Nascimento, Jinhong Shin, et al.
Nature Medicine|June 27, 2025
AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trialRussell J Butterfield, Perry B Shieh, Huihua Li, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 30, 2025
Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophyBarry J Byrne, Russell J Butterfield, Perry B Shieh, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Kidney International Reports|October 8, 2021
A Retrospective Study of Clinical and Economic Burden of Focal Segmental Glomerulosclerosis (FSGS) in the United StatesKamyar Kalantar-Zadeh, Christine L Baker, J Brian Copley, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 13, 2023
Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapyMartin Schulz, Daniel I Levy, Christos J Petropoulos, et al.
Clinical Transplantation|January 31, 2014
Long-term evaluation of analytical methods used in sirolimus therapeutic drug monitoringDavid W Holt, Didier A Mandelbrot, Michael A Tortorici, et al.
Kidney International Reports|June 25, 2021
PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental GlomerulosclerosisLaurence H Beck, Stephen P Berasi, J Brian Copley, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 30, 2025
Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trialSarah P Sherlock, Daniel I Levy, Avery McIntosh, et al.
The Lancet. Neurology|February 21, 2026
Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled studyFrancesco Muntoni, Andres Nascimento, Jinhong Shin, et al.
Nature Medicine|June 27, 2025
AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trialRussell J Butterfield, Perry B Shieh, Huihua Li, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 30, 2025
Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophyBarry J Byrne, Russell J Butterfield, Perry B Shieh, et al.
Pageof 2